01

Phase 3 melanoma vaccine cuts recurrence or death risk by 42%

Sponsor-reported phase 3 INTerpath-001 data show intismeran plus pembrolizumab reduced melanoma recurrence or death risk by 42% and distant metastasis or death risk by 38%.